drugset / Trial / NCT04542434
Niclosamide in COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
Timeline
- Start
- 2022-01-20
- Primary completion
- 2022-01-20
- Completion
- 2022-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niclosamide | Unknown | 400 mg | Oral |